

United States District Court
Northern District of California

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

PLEXXIKON INC.,
Plaintiff,
v.
NOVARTIS PHARMACEUTICALS
CORPORATION,
Defendant.

Case No. [17-cv-04405-HSG](#)

ORDER GRANTING IN PART AND DENYING IN PART MOTIONS TO SEAL

Re: Dkt. Nos. 149, 164, 166, 168, 176, 178, 185, 187, 193, 196, 199, 201, 203, 205, 207, 209, 211, 224, 226, 231, 232, 235, 242, 258, 261, 263, 265, 267, 282, 285, 287, 289, 291, 293, 295, 297, 299, 306, 314, 332, 363, 366, 368, 374

Pending before the Court are the parties’ administrative motions to file under seal portions of documents in connection with motions for partial summary judgment, Daubert motions, and motions in limine filed by Plaintiff Plexxikon Inc. and Defendant Novartis Pharmaceuticals Corporation (twenty-eight total). For the reasons detailed below, the Court **GRANTS IN PART** and **DENIES IN PART** the motions to file under seal.

I. LEGAL STANDARD

Courts generally apply a “compelling reasons” standard when considering motions to seal documents. *Pintos v. Pac. Creditors Ass’n*, 605 F.3d 665, 678 (9th Cir. 2010) (quoting *Kamakana v. City & Cty. of Honolulu*, 447 F.3d 1172, 1178 (9th Cir. 2006)). “This standard derives from the common law right ‘to inspect and copy public records and documents, including judicial records and documents.’” *Id.* (quoting *Kamakana*, 447 F.3d at 1178). “[A] strong presumption in favor of access is the starting point.” *Kamakana*, 447 F.3d at 1178 (quotations omitted). To overcome this strong presumption, the party seeking to seal a judicial record attached to a dispositive motion must “articulate compelling reasons supported by specific factual findings that outweigh the general history of access and the public policies favoring disclosure, such as the public interest in

1 understanding the judicial process” and “significant public events.” Id. at 1178–79 (quotations
2 omitted). “In general, ‘compelling reasons’ sufficient to outweigh the public’s interest in
3 disclosure and justify sealing court records exist when such ‘court files might have become a
4 vehicle for improper purposes,’ such as the use of records to gratify private spite, promote public
5 scandal, circulate libelous statements, or release trade secrets.” Id. at 1179 (quoting *Nixon v.*
6 *Warner Commc’ns, Inc.*, 435 U.S. 589, 598 (1978)). “The mere fact that the production of records
7 may lead to a litigant’s embarrassment, incrimination, or exposure to further litigation will not,
8 without more, compel the court to seal its records.” Id.

9 Civil Local Rule 79-5 supplements the “compelling reasons” standard. The party seeking
10 to file under seal must submit “a request that establishes that the document, or portions thereof, are
11 privileged, protectable as a trade secret or otherwise entitled to protection under the law The
12 request must be narrowly tailored to seek sealing only of sealable material” Civil L.R. 79-
13 5(b). Courts have found that “confidential business information” in the form of “license
14 agreements, financial terms, details of confidential licensing negotiations, and business strategies”
15 satisfies the “compelling reasons” standard. See *In re Qualcomm Litig.*, No. 3:17-cv-0108-GPC-
16 MDD, 2017 WL 5176922, at *2 (S.D. Cal. Nov. 8, 2017) (observing that sealing such information
17 “prevent[ed] competitors from gaining insight into the parties’ business model and strategy”);
18 *Finisar Corp. v. Nistica, Inc.*, No. 13-cv-03345-BLF (JSC), 2015 WL 3988132, at *5 (N.D. Cal.
19 June 30, 2015).

20 Records attached to nondispositive motions must meet the lower “good cause” standard of
21 Rule 26(c) of the Federal Rules of Civil Procedure, as such records “are often unrelated, or only
22 tangentially related, to the underlying cause of action.” Id. at 1179–80 (quotations omitted). This
23 requires a “particularized showing” that “specific prejudice or harm will result” if the information
24 is disclosed. *Phillips ex rel. Estates of Byrd v. Gen. Motors Corp.*, 307 F.3d 1206, 1210–11 (9th
25 Cir. 2002); see also Fed. R. Civ. P. 26(c). “Broad allegations of harm, unsubstantiated by specific
26 examples of articulated reasoning” will not suffice. *Beckman Indus., Inc. v. Int’l Ins. Co.*, 966
27 F.2d 470, 476 (9th Cir. 1992) (quotation omitted).

28 //

1 **II. DISCUSSION**

2 Because the parties seek to seal portions and documents which pertain to summary
3 judgment motions, the Court applies the compelling reasons standard to these documents. The
4 Court applies the lower good cause standard for those documents related to the parties’ Daubert
5 motions and motions in limine.

6 As indicated in the table below, the only proffered justification for sealing many of the
7 documents is that the information was designated as “highly confidential” by either Plaintiff,
8 Defendant, or non-parties GlaskoSmithKline PLC and GlaskoSmithKline LLC. But a designation
9 of confidentiality is not sufficient to establish that a document is sealable. See Civ. L. R. 79-
10 5(d)(1)(A). “Confidential” is merely the parties’ initial designation of confidentiality to establish
11 coverage under the stipulated protective order. See *Verinata Health, Inc. v. Ariosa Diagnostics,*
12 *Inc.*, No. 12-cv-05501-SI, 2015 WL 5117083, at *5 (N.D. Cal. Aug. 31, 2015) (“But good cause
13 ‘cannot be established simply by showing that the document is subject to a protective order or by
14 stating in general terms that the material is considered to be confidential’”) (quoting *Bain v.*
15 *AstraZeneca LP*, No. 09-cv-4147, 2011 WL 482767, at *1 (N.D. Cal. Feb. 7, 2011)). Thus, many
16 of the parties’ motions do not comply with Civil Local Rule 79-5(d)(1)(A). In addition, in many
17 instances the designating party for the materials did not comply with Civil Local Rule 79-5(e)(1),
18 because they did not file a declaration within four days of the motion. See Civ. L.R. 79-5(e)(1).
19 The Court finds that sealing is not warranted as to those documents.

20 Nevertheless, the Court finds that as to the remaining motions to seal, the parties have
21 narrowly tailored their requested redactions to confidential and proprietary business, scientific,
22 manufacturing, sales, or licensing information. The public release of these documents could give
23 non-party competitors an unfair advantage in the development or marketing of rival products. See
24 *In re Elec. Arts, Inc.*, 298 F. App’x 568, 569 (9th Cir. 2008) (ordering sealing where documents
25 could be used “‘as sources of business information that might harm a litigant’s competitive
26 standing’”) (quoting *Nixon v. Warner Commc ’ns, Inc.*, 435 U.S. 589, 598 (1978)). Thus, the
27 Court finds that the parties have in those circumstances established either compelling reasons or
28 good cause to grant the motions to file under seal. See, e.g., *Linex Techs., Inc. v. Hewlett-Packard*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Co., No. C 13-159 CW, 2014 WL 6901744 (N.D. Cal. Dec. 8, 2014); Apple Inc. v. Samsung Elecs. Co., Ltd., No. 11-CV-01846-LHK, 2012 WL 6115623 (N.D. Cal. Dec. 10, 2012).

Docket No. Public /(Sealed)	Document	Portion(s) Sought to be Sealed	Ruling
Dkt. No. 149 – GRANTED			
Dkt. No. 150-1/ (149-4)	Exhibit A to the Declaration of Daralyn J. Durie in Support of March 18, 2019 Discovery Letter	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 153.)
Dkt. No. 164 – DENIED			
Dkt. No. 165/ (164-4)	Plaintiff’s Notice of Motion and Motion to Exclude Certain Opinions and Testimony of Novartis’s Technical Experts	Page 2:15–28 Page 3:1–13, 18–20 Page 4:4–15, 19–20 Page 5:5–12, 18–20, 24–26 Page 6:13–15 Page 8:19–24 Page 9:1–5 Page 10:1–6, 15–22, 27–28 Page 11:25–28 Page 12:1–2, 9–11	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 165-2/ (164-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff’s Motion to Exclude the Opinions and Testimony of Novartis’s Technical Experts	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 165-3/ (164-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Motion to Exclude the Opinions and Testimony of Novartis’s Technical Experts	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 165-5/ (164-10)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Motion to Exclude the Opinions and Testimony of Novartis’s	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Technical Experts		
Dkt. No. 165-6/ (164-12)	Exhibit 5 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Exclude the Opinions and Testimony of Novartis's Technical Experts	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 165-8/ (164-14)	Exhibit 7 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Exclude the Opinions and Testimony of Novartis's Technical Experts	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 166 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 167/ (166-4)	Plaintiff's Notice of Motion and Motion for Summary Judgment of No Anticipation	Page 1:8–9, 13–18 Page 2:9 Page 5:17–22, 26–28 Page 6:1–10 Page 11:13–22 Page 12:3, 6–18, 20 Page 13:17–18, 20–24 Page 14:1–2 Page 15:13–14, 21–24 Page 16:1–7, 10, 12 Page 17:13–14	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 167-2/ (166-6)	Exhibit 1 to the Declaration of Matthew W. Samuels in Support of Plaintiff's Motion for Summary Judgment of No Anticipation	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 167-10/ (166-8)	Exhibit 9 to the Declaration of Matthew W. Samuels in Support of Plaintiff's Motion for Summary Judgment of No Anticipation	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 167-20/ (166-10)	Exhibit 19 to the Declaration of Matthew W. Samuels in Support of Plaintiff's Motion for Summary Judgment of No Anticipation	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 167-21/ (166-12)	Exhibit 20 to the Declaration of Matthew W. Samuels in Support of	Entire document	GRANTED (Contains proprietary pharmaceutical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Plaintiff’s Motion for Summary Judgment of No Anticipation		research and development information. See Dkt. No. 171.)
Dkt. No. 167-22/ (166-14)	Exhibit 21 to the Declaration of Matthew W. Samuels in Support of Plaintiff’s Motion for Summary Judgment of No Anticipation	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 171.)
Dkt. No. 168 – DENIED			
Dkt. No. 169/ (168-10)	Plaintiff’s Notice of Motion and Motion to Exclude the Opinions and Testimony of James E. Malackowski	Page i:7–10 Page 1:6–9, 12–15, 20 Page 2:7–10, 16–28 Page 3:1–28 Page 4:1–6 Page 7:3–28 Page 8:1–2, 4–15, 19–20, 26–27 Page 9:8–17 Page 10:1–7, 16–28 Page 11:1, 11–12, 14–24 Page 12:4–5, 16–28 Page 13:1–14, 17–28 Page 14:1–17, 19–20	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 169-1/ (168-4)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff’s Motion to Exclude the Opinions and Testimony of James E. Malackowski	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 169-3/ (168-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Motion to Exclude the Opinions and Testimony of James E. Malackowski	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 169-4/ (168-8)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff’s Motion to Exclude the Opinions and Testimony of James E. Malackowski	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dkt. No. 176 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 177/ (176-4)	Defendant’s Notice of Motion and Motion for Partial Summary Judgment	Page 2:16, 24–28 Page 3:6–14, 21–26 Page 4:1–2, 7–11 Page 5:11–26 Page 6:1–13 Page 7:2–18, 20 Page 8:8–12, 26–27 Page 9:1–2, 6–15 Page 12:28 Page 13:1, 5–8, 10–18 Page 14:5–9 Page 15:25–27 Page 16:21–22 Page 17:15–18	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page 3:6–14, 21–26 • Page 4:1–2, 7–11 • Page 5:11–26 • Page 6:1–13 • Page 12:28 • Page 13:1, 5–8, 10–18 • Page 14:5–9 See Dkt. No. 182.)
Dkt. No. 177-16/ (176-12)	Declaration of Tara R. Rheault, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Page 2:3, 7, 10, 23, 25–26 Page 3:1–27 Page 4:1, 3–12	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 182.)
Dkt. No. 177-17/ (176-13)	Exhibit 1 to the Declaration of Tara R. Rheault, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 182.)
Dkt. No. 177-18/ (176-14)	Exhibit 2 to the Declaration of Tara R. Rheault, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 182.)
Dkt. No. 177-2/ (176-6)	Declaration of Phil S. Baran, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Page 2:11–16, 18–27 Page 3:1, 11–18 Page 4:9–13 Page 5:5–23, 25–26 Appendix A, pp. 1–3, 9–11, 19 Appendix B in its entirety	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 182.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dkt. No. 177-6/ (Native Excel File)	Exhibit 4 to the Declaration of Phil S. Baran, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Entire document	GRANTED (Contains trade secrets, as well as proprietary pharmaceutical research and development information. See Dkt. No. 182.)
Dkt. No. 177-7/ (176-7)	Exhibit 5 to the Declaration of Phil S. Baran, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Entire document	GRANTED (Contains trade secrets, as well as proprietary pharmaceutical research and development information. See Dkt. No. 182.)
Dkt. No. 177-8/ (176-8)	Exhibit 6 to the Declaration of Phil S. Baran, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Entire document	GRANTED (Contains trade secrets, as well as proprietary pharmaceutical research and development information. See Dkt. No. 182.)
Dkt. No. 177-9/ (176-9)	Exhibit 7 to the Declaration of Phil S. Baran, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Entire document	GRANTED (Contains trade secrets, as well as proprietary pharmaceutical research and development information. See Dkt. No. 182.)
Dkt. No. 177-14/ (176-10)	Exhibit 12 to the Declaration of Phil S. Baran, PhD., In Support of Defendant’s Motion for Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 177-20/ (176-15)	Exhibit 1 to the Declaration Of Thomas P. Steindler In Support Of Defendant’s Motion For Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dkt. No. 177-22/ (176-16)	Exhibit 3 to the Declaration Of Thomas P. Steindler In Support Of Defendant's Motion For Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 178 – DENIED			
Dkt. No. 179/ (178-4)	Defendant's Notice of Motion and Motion to Strike Portions of Expert Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Page i:12 Page 2:2–3, 5–6, 8, 9, 12–15, 18–19, 21 Page 5:10–12, 16–23 Page 6:8 Page 7:5, 7, 10, 15, 18–19, 20, 24 Page 8:3, 7, 11, 16, 20, 27–28 Page 9:1–2, 16	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 179-3/ (178-5)	Exhibit 1 to the Declaration of David Mlaver In Support Of Defendant's Motion To Strike Portions of Expert Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 179-7/ (178-7)	Exhibit 5 to the Declaration of David Mlaver In Support Of Defendant's Motion To Strike Portions of Expert Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Pages 12–15	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 179-9/ (178-8)	Exhibit 7 to the Declaration of David Mlaver In Support Of Defendant's Motion To Strike Portions of Expert Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 185 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 186/ (185-4)	Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation	Page 4:8, 13 Page 5:13 Page 7:25 Page 10:7 Page 14:1–2, 5, 24–25 Page 15:6–21	GRANTED IN PART (The following contains proprietary pharmaceutical research and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

		Page 16:12–13, 23–25 Page 17:15–16, 20–21 Page 18:15–18, 24–26 Page 19:8–9	development information: • Page 15:10–17 See Dkt. No. 190.)
Dkt. No. 186-3/ (185-5)	Exhibit 2 to the Declaration of Thomas P. Steindler In Support Of Defendant’s Opposition To Plaintiff’s Motion For Summary Judgment Of No Anticipation	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 186-4/ (185-7)	Exhibit 3 to the Declaration of Thomas P. Steindler In Support Of Defendant’s Opposition To Plaintiff’s Motion For Summary Judgment Of No Anticipation	¶¶ 80–84, 86–87, 99–108	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: • ¶¶ 86, 104, 107, 108 See Dkt. No. 190.)
Dkt. No. 186-6/ (185-8)	Exhibit 5 to the Declaration of Thomas P. Steindler In Support Of Defendant’s Opposition To Plaintiff’s Motion For Summary Judgment Of No Anticipation	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 186-8/ (185-9)	Exhibit 7 to the Declaration of Thomas P. Steindler In Support Of Defendant’s Opposition To Plaintiff’s Motion For Summary Judgment Of No Anticipation	Entire document	DENIED (Defendant states, in conclusory fashion, that the documents “contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis.” See Dkt. No. 185-1. This generic explanation is insufficient to establish good cause.)
Dkt. No. 186-9/ (185-10)	Exhibit 8 to the Declaration of Thomas P. Steindler In Support Of	Entire document	GRANTED (Contains proprietary pharmaceutical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation		research and development information. See Dkt. No. 190.)
Dkt. No. 186-10/ (185-11)	Exhibit 9 to the Declaration of Thomas P. Steindler In Support Of Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 190.)
Dkt. No. 186-11/ (185-12)	Exhibit 10 to the Declaration of Thomas P. Steindler In Support Of Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 186-12/ (185-13)	Exhibit 11 to the Declaration of Thomas P. Steindler In Support Of Defendant's Opposition To Plaintiff's Motion For Summary Judgment Of No Anticipation	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 187 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 188/ (187-4)	Defendant's Opposition To Plaintiff's Motion To Exclude The Opinions And Testimony Of James E. Malackowski	Page i:8–10 Page 1:7–8, 10, 15–16, 21 Page 2:19–27 Page 3:1–15, 18–19, 23, 25–26 Page 5:3–5, 8, 13, 16, 19–20, 23, 25–26 Page 6:5 Page 7:12–14, 16–19, 23 Page 8:7, 13–17, 19, 20, 22, 24–28 Page 9:3, 6–7 Page 10:5–7, 16–20, 25–28 Page 11:1–2, 27–28	DENIED (Defendant states, in conclusory fashion, that the documents “contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis.” See Dkt. No. 187-1. This generic explanation is insufficient to establish good cause.)
Dkt. No. 188-2/ (187-5)	Exhibit A to the Declaration of Tom Steindler in Support of Defendant's Opposition To Plaintiff's Motion To Exclude The Opinions And Testimony Of James	Entire document	GRANTED IN PART (Pages 12, 52–63 contain trade secrets and highly confidential licensing information. See Dkt.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	E. Malackowski		No. 191. As to the rest of the document, Defendant states, in conclusory fashion, that it “contain[s] and refer[s] to competitively sensitive” information. See Dkt. No. 187-1. This generic explanation is insufficient to establish good cause.)
Dkt. No. 188-3/ (187-6)	Exhibit B to the Declaration of Tom Steindler in Support of Defendant’s Opposition To Plaintiff’s Motion To Exclude The Opinions And Testimony Of James E. Malackowski	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 188-4/ (187-7)	Exhibit C to the Declaration of Tom Steindler in Support of Defendant’s Opposition To Plaintiff’s Motion To Exclude The Opinions And Testimony Of James E. Malackowski	Entire document	DENIED (Defendant states, in conclusory fashion, that the documents “contain and refer to competitively sensitive documents the public disclosure of which would cause harm to Novartis.” See Dkt. No. 187-1. This generic explanation is insufficient to establish good cause.)
Dkt. No. 193 – DENIED			
Dkt. No. 194/ (193-4)	Plaintiff’s Reply in Support of Its Motion to Exclude the Opinions and Testimony of James E. Malackowski	Page i:5–9 Page 1:5, 8–14, 17, 23–24 Page 2:9–11 Page 3:2, 27 Page 4:8–12, 21–25, 27–28 Page 5:1–2, 12–13, 15–16, 25–28 Page 6:1–2, 4–9, 14–17, 23–26 Page 8:3–13	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

		Page 9:9–10	
Dkt. No. 196 – DENIED			
Dkt. No. 197/ (196-4)	Plaintiff’s Reply in Support of Its Motion to Exclude Certain Opinions and Testimony of Novartis’s Technical Experts	Page 3:3–14 Page 5:6–8, 24–28 Page 6:1–18 Page 7:2–6	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 199 – DENIED			
Dkt. No 200/ (199-4)	Defendant’s Notice of Motion and Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Page 2:14, 22–28 Page 3:1–12, 14–26 Page 4:1–10 Page 5:23 Page 6:7–8, 11–13, 17–21, 24–25, 27–28 Page 7:5–6, 8–11, 14–28 Page 8:1–6, 16–17, 20–26 Page 9:3–6, 9, 10–13, 16–19, 21, 22–24, 26–27 Page 10:1–11, 20–24 Page 11:6–8 Page 12:20, 24	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 200-1/ (199-6)	Declaration of Phil S. Baran, Ph.D. In Support Of Defendant’s Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	¶¶ 17–28, 30–35, 37–45, 47, 49, 58, 59	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 200-5/ (199-7)	Exhibit 3 to the Declaration of Tom Steindler in Support of Defendant’s Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 200-6/ (199-8)	Exhibit 4 to the Declaration of Tom Steindler in Support of Defendant’s Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 200-7/ (199-9)	Exhibit 5 to the Declaration of Tom Steindler in Support of Defendant’s Motion to Exclude Expert Testimony of Michael L. Metzker,	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Ph.D.		
Dkt. No. 200-8/ (199-10)	Exhibit 6 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 200-9/ (199-11)	Exhibit 7 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 200-10/ (199-12)	Exhibit 8 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Michael L. Metzker, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 201 – DENIED			
Dkt. No. 202/ (201-4)	Defendant's Notice of Motion and Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 1:22–28 Page 2:1–16, 18–28 Page 3:1–13 Page 5:5–12, 15–24 Page 6, lines 15-28 Page 7, lines 1-3, 6-11	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 202-2/ (201-5)	Exhibit 1 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 202-3/ (201-6)	Exhibit 2 to the Declaration of Tom Steindler in Support of Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 203 – DENIED			
Dkt. No. 204/ (203-4)	Defendant's Notice of Motion and Motion to Preclude Certain Testimony of Dr. Susana	Page 1:20–25 Page 2:1, 4–25 Page 3:1–5 Page 7:21–23, 25–28	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Ortiz-Urda Under Daubert	Page 8:1	
Dkt. No. 204-2/ (203-5)	Exhibit 1 to the Declaration of Tom Steindler in Support of Defendant’s Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 204-3/ (203-6)	Exhibit 2 to the Declaration of Tom Steindler in Support of Defendant’s Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 205 – DENIED			
Dkt. No. 206/ (205-4)	Defendant’s Notice of Motion and Motion to Exclude Expert Testimony of Ted Sweeney	Page 2:6–7, 21 Page 6:2–5, 18–20	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 206-2/ (205-5)	Exhibit 1 to the Declaration of Tom Steindler in Support of Defendant’s Motion to Exclude Expert Testimony of Ted Sweeney	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 207 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 208/ (207-4)	Plaintiff’s Opposition to Defendant’s Motion to Strike Portions of Report of Plaintiff’s Expert Michael L. Metzker, Ph.D.	Page 1:3–4, 6 Page 3:2–3, 22, 24 Page 4:4–5, 28 Page 5:2–4 Page 9:13–14, 16	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 221.)
Dkt. No. 208-1/ (207-6)	Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Defendant’s Motion to Strike Portions of Report of Plaintiff’s Expert Michael L. Metzker, Ph.D.	Page 2:3–4	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 221.)
Dkt. No. 208-5/ (207-8)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Defendant’s Motion to Strike Portions of Report	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	of Plaintiff's Expert Michael L. Metzker, Ph.D.		No. 221.)
Dkt. No. 208-10/ (207-10)	Exhibit 9 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Strike Portions of Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Page 11:10–11, 14–16, 18–21 Page 14:27–28 Page 15:3–9	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 221.)
Dkt. No. 208-14/ (207-12)	Exhibit 13 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Strike Portions of Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Entire document	GRANTED (Contains trade secrets, as well as proprietary pharmaceutical research and development information. See Dkt. No. 221.)
Dkt. No. 208-15/ (207-14)	Exhibit 14 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Strike Portions of Report of Plaintiff's Expert Michael L. Metzker, Ph.D.	Page 10:13–16, 26 Page 31:11–17	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 209 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 210/ (209-4)	Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Page i:8–9 Page 2:7–9 Page 5:17–28 Page 6:1, 3–10, 18–22, 24–28 Page 7:1–2, 4 Page 8:6–13, 18–20 Page 9:3–4, 6–7, 9–10 Page 14:15–17 Page 15:4–5, 7–9, 11, 13–14 Page 17:4–11, 26–27 Page 21:23–25 Page 22:1–2	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page 6:5–10, 12–22, 24–28 • Page 7:1–2, 4 See Dkt. No. 223.)
Dkt. No. 210-6/ (209-6)	Exhibit 5 to the Declaration of Laura E. Miller in Support of	Entire document	GRANTED (Contains proprietary pharmaceutical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Plaintiff’s Opposition to Novartis Pharmaceuticals Corporation’s Motion for Judgment on the Pleadings		research and development information. See Dkt. No. 223.)
Dkt. No. 210-7/ (209-8)	Exhibit 6 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis Pharmaceuticals Corporation’s Motion for Judgment on the Pleadings	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 223.)
Dkt. No. 210-8/ (209-10)	Exhibit 7 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis Pharmaceuticals Corporation’s Motion for Judgment on the Pleadings	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 223.)
Dkt. No. 210-9/ (209-12)	Exhibit 8 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis Pharmaceuticals Corporation’s Motion for Judgment on the Pleadings	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 223.)
Dkt. No. 210-10/ (209-14)	Exhibit 9 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis Pharmaceuticals Corporation’s Motion for Judgment on the Pleadings	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 210-11/ (209-16)	Exhibit 10 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis Pharmaceuticals Corporation’s Motion for Judgment on the Pleadings	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 210-12/ (209-18)	Exhibit 11 to the Declaration of Laura E. Miller in Support of	Entire document	DENIED (No supporting declaration filed. See

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings		Civ. L.R. 79-5(e)(1).)
Dkt. No. 210-13/ (209-20)	Exhibit 12 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 210-14/ (209-22)	Exhibit 13 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis Pharmaceuticals Corporation's Motion for Judgment on the Pleadings	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 211 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 212/ (211-4)	Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment	Page i:11–13 Page 1:3–5, 17, 19–21, 23, 28 Page 8:2, 4, 28 Page 9:1–4, 7, 24–28 Page 10:1, 7–13, 22–24, 26–28 Page 11:4, 7–9 Page 15:19 Page 16:12–13 Page 17:10–12	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page i:11–13 • Page 1:3–5, 17, 23, 28 • Page 8:2, 4, 28 • Page 9:1–4, 24–28 • Page 10:1, 7–13, 22–24, 26–28 • Page 11:4, 7–9 • Page 15:19 • Page 16:12–13 See Dkt. No. 222.)
Dkt. No. 213-1/ (211-6)	Exhibit A to the Declaration of Michael L. Metzker in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary	Page 42:1–25 Page 43:1–6	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Judgment		
Dkt. No. 213-2/ (211-8)	Exhibit B to the Declaration of Michael L. Metzker in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment	Page 10:15–16, 26 Page 15:10–22, 14–16, 18–20, 26–27 Page 16:1, 18–20, 23–24 Page 27:17 Page 31:11–19 Page 46:20–21 Page 62:1, 3, 6–12, 14–15, 26 Page 63:1–4, 7–8, 26 Page 64:9–11 Page 65:2, 7–9, 11–12, 14, 18, 20–22 Page 66:23–26 Page 67:1–2, 4, 6–24 Page 106:1–3, 5, 11–12, 15–18	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page 62:1, 3, 6–12, 14–15, 26 • Page 63:1–4 • Page 65:18 • Page 66:23–26 • Page 67:1–2, 4, 6–24 • Page 106:1–3. See Dkt. No. 222.)
Dkt. No. 212-13/ (211-10)	Exhibit 12 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 212-20/ (211-12)	Exhibit 19 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 214-1/ (211-14)	Exhibit A to the Declaration of Jeffrey Winkler in Support of Plaintiff's Opposition to Defendant's Motion for Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 224 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 325/ (224-4)	Plaintiff's Opposition to Defendant's Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 1:17–18 Page 4:6–7 Page 5:1	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 325-2/ (224-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of	Page 31, ¶¶ 62–63 Page 32, ¶¶ 63–65 Page 33, ¶¶ 65–66, n.88	GRANTED IN PART (The following

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Plaintiff’s Opposition to Defendant’s Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 34, ¶ 68 Page 35, ¶ 69, n.93, 95 Page 36, ¶ 70 Page 37, ¶ 72 Page 38, ¶¶ 72–73, n.102, 104 Page 39, ¶¶ 73–74, n.107 Page 40, n.110 Page 44, ¶ 81 Page 72, ¶¶ 124–125 Page 73, ¶ 125 Page 74, ¶ 128, n.219 Page 75, ¶¶ 128–129 Page 76, ¶¶ 131–132, n.222 Page 77, ¶¶ 132–135 Page 81, ¶ 147	contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page 44, ¶ 81 • Page 71–72, ¶ 124 • Page 76, n.222 • Page 77, ¶¶ 133, 135 See Dkt. No. 237.)
Dkt. No. 325-3/(224-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Defendant’s Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 45, n.133 Page 46, ¶ 74	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 226 – DENIED			
Dkt. No. 227/(226-4)	Plaintiff’s Opposition to Defendant’s Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert	Page 3:7–13, 16–21 Page 5:14–15, 21–24 Page 6:22–27 Page 9:8–10	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 227-2/(226-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Defendant’s Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert	Page 9, ¶ 20 Page 22, ¶ 50 Page 25, n.52 Page 26, ¶ 59, n.54 Page 27, ¶¶ 60, 61 Page 28, ¶ 63, n.61 Page 29, ¶ 66	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 227-3/(226-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Defendant’s Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dkt. No. 231 – DENIED			
Dkt. No. 233/ (231-4)	Defendant’s Reply in Support of Motion for Partial Summary Judgment	Page 1:15–17 Page 2:6–7 Page 3:4–5 Page 6:5–8, 12–13, 21, 23–24 27–28 Page 7:1–4, 8 13, 16, 26–28 Page 11:20–28 Page 12:8 Page 13:20–23 Page 15:8–10, 13–14, 17	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 233-2/ (231-6)	Exhibit A to the Declaration of Thomas Steindler in Support of Reply in Support of Motion for Partial Summary Judgment	Pages 12–15	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 233-3/ (231-7)	Exhibit B to the Declaration of Thomas Steindler in Support of Reply in Support of Motion for Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 233-4/ (231-8)	Exhibit C to the Declaration of Thomas Steindler in Support of Reply in Support of Motion for Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 233-5/ (231-9)	Exhibit D to the Declaration of Thomas Steindler in Support of Reply in Support of Motion for Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 233-6/ (231-10)	Exhibit E to the Declaration of Thomas Steindler in Support of Reply in Support of Motion for Partial Summary Judgment	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 232 – DENIED			
Dkt. No. 234/ (232-4)	Plaintiff’s Opposition to Defendant’s Motion to Exclude Expert Testimony of Ted Sweeney	Page 3:25–28 Page 4:1–2, 5–20 Page 6:7 Page 7:24–25 Page 8:11–14, 23, 28	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

		Page 9:15, 28 Page 11:21, 27-28 Page 12:17, 28 Page 13:5-7, 12-13, 26	
Dkt. No. 234-3/ (232-6)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Exclude Expert Testimony of Ted Sweeney	Page 13:12-13, 15-26 Page 14:5, 7-17 Page 23:22-23 Page 24:7-12 Page 25:16-27 Page 26:1-10, 12-14	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 234-5/ (232-8)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Exclude Expert Testimony of Ted Sweeney	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 234-6/ (232-10)	Exhibit 5 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Defendant's Motion to Exclude Expert Testimony of Ted Sweeney	Page 1:19-21, 23-26, 28 Page 2:1-3, 6-7, 12-16, 27-28 Page 3:1-3, 11-12 Page 4:3, 5 Page 5:17-18 Page 6:15-16 Page 7:19-27 Page 8:1-2, 10-15	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 235 – DENIED			
Dkt. No. 236/ (235-4)	Plaintiff's Motion to Strike Defendant's Daubert Motions Filed June 6, 2019	Page 4:27-28 Page 5:1	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 236-2/ (235-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Strike Defendant's Daubert Motions Filed June 6, 2019	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 236-3/ (235-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion to Strike Defendant's Daubert Motions Filed June 6, 2019	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 242 – GRANTED			
Dkt. No. 242-3/	Exhibit 5 to the	Entire document	GRANTED

1	(Native Excel File)	Declaration of Tom Steindler in Support of Defendant's Reply in Support of Motion to Preclude Certain Testimony of Dr. Susana Ortiz-Urda Under Daubert		(Contains licensing and proprietary pharmaceutical research and development information. See Dkt. No. 242.)
Dkt. No. 258 – DENIED				
2	Dkt. No. 259/ (258-4)	Plaintiff's Motion In Limine No. 1 Excluding Undisclosed Validity Challenges	Page 1:24–28 Page 2:1–3, 15–18 Page 3:1–3	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
3	Dkt. No. 259-2/ (258-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion in Limine No. 1 Excluding Undisclosed Validity Challenges	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
4	Dkt. No. 259-3/ (258-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Motion in Limine No. 1 Excluding Undisclosed Validity Challenges	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 261 – DENIED				
5	Dkt. No. 262/ (261-4)	Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony	Page 1:8–9 Page 2:2–22 Page 3:2–3	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
6	Dkt. No. 262-2/ (261-6)	Exhibit 1 of the Declaration Of Laura E. Miller In Support Of Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
7	Dkt. No. 262-3/ (261-8)	Exhibit 2 of the Declaration Of Laura E. Miller In Support Of Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
8	Dkt. No. 262-4/ (261-10)	Exhibit 3 of the Declaration Of Laura E. Miller In Support Of	Entire document	DENIED (No supporting declaration filed. See

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony		Civ. L.R. 79-5(e)(1).)
Dkt. No. 262-5/ (261-12)	Exhibit 4 of the Declaration Of Laura E. Miller In Support Of Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 262-6/ (261-14)	Exhibit 5 of the Declaration Of Laura E. Miller In Support Of Plaintiff's Motion In Limine No. 3 Re: Cumulative Expert Testimony	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 263 – DENIED			
Dkt. No. 264/ (263-4)	Plaintiff's Motion In Limine No. 4 re: Excluding Withheld Evidence	Page 2:25–28 Page 3:1–3 Page 3:7–9 Page 4:28 Page 5:1	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 264-1/ (263-6)	Declaration of Laura E. Miller In Support of Plaintiff's Motion In Limine No. 4 re: Excluding Withheld Evidence	Page 1:17–19	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 264-6/ (263-8)	Exhibit 5 to the Declaration of Laura E. Miller In Support of Plaintiff's Motion In Limine No. 4 re: Excluding Withheld Evidence	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 264-7/ (263-10)	Exhibit 6 to the Declaration of Laura E. Miller In Support of Plaintiff's Motion In Limine No. 4 re: Excluding Withheld Evidence	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 265 – GRANTED			
Dkt. No. 266/ (265-4)	Plaintiff's Motion in Limine No. 5 re: Excluding Hidden	Page 1:20–25 Page 2:2–3, 7–9	GRANTED (Contains proprietary pharmaceutical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Hearsay Testimony		research and development information. See Dkt. No. 274.)
Dkt. No. 266-2/ (265-6)	Exhibit 1 to the Declaration of Laura E. Miller in support of Plaintiff's Motion in Limine No. 5 re: Excluding Hidden Hearsay Testimony	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 274.)
Dkt. No. 267 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 273-5/ (267-5)	Exhibit E to the Declaration of Thomas P. Steindler In Support of Novartis's Motions in Limine	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 267-1.)
Dkt. No. 273-6/ (267-7)	Exhibit F to the Declaration of Thomas P. Steindler In Support of Novartis's Motions in Limine	Page i:11–13 Page 1:3–5, 17, 19–21, 23, 28 Page 8:2, 4, 28 Page 9:1–4, 7, 24–28 Page 10:1, 7–13, 22–24, 26–28 Page 11:4, 7–9 Page 15:19 Page 16:12–13 Page 17:10–12	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page i:11–13 • Page 1:3–5, 17, 23, 28 • Page 8:2, 4, 28 • Page 9:1–4, 24–28 • Page 10:1, 7–13, 22–24, 26–28 • Page 11:4, 7–9 • Page 15:19 • Page 16:12–13 See Dkt. No. 222.)
Dkt. No. 273-7/ (267-9)	Exhibit G to the Declaration of Thomas P. Steindler In Support of Novartis's Motions in Limine	Page i:8–9 Page 2:7–9 Page 5:17–28 Page 6:1, 3–10, 18–22, 24–28 Page 7:1–2, 4 Page 8:6–13, 18–20 Page 9:3–4, 6–7, 9–10 Page 14:15–17	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page 6:5–10, 12–

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

		Page 15:4-5, 7-9, 11, 13-14 Page 17:4-11, 26-27 Page 21:23-25 Page 22:1-2	22, 24-28 • Page 7:1-2, 4 See Dkt. No. 223.)
Dkt. No. 273-11/ (267-10)	Exhibit K to the Declaration of Thomas P. Steindler In Support of Novartis's Motions in Limine	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 272/ (267-4)	Novartis's Motion in Limine No. 5 re: Evidence or Argument Suggesting Damages Should Be Awarded for Any Period After December 2018	Page 1:12-26 Page 2:25-26	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 282 – DENIED			
Dkt. No. 283/ (282-4)	Opposition To Plexxikon's Motion in Limine No. 1 re: Excluding Undisclosed Validity Challenges	Page 2:12-13, 19-20, 23-24 Page 3:5-8	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 285 – DENIED			
Dkt. No. 286-2/ (285-4)	Exhibit A to the Declaration of Thomas P. Steindler In Support of Opposition To Plexxikon's Motion in Limine No. 3 re: Cumulative Expert Testimony	¶¶ 3, 7, 17, 21, 25, 26, 28-31, 75-78, 115-122, 126, 127	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 286-7/ (285-6)	Exhibit F to the Declaration of Thomas P. Steindler In Support of Opposition To Plexxikon's Motion in Limine No. 3 re: Cumulative Expert Testimony	¶ 3	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 286-9/ (285-8)	Exhibit H to the Declaration of Thomas P. Steindler In Support of Opposition To Plexxikon's Motion in Limine No. 3 re: Cumulative Expert Testimony	¶¶ 61-65	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dkt. No. 286-10/ (285-10)	Exhibit I to the Declaration of Thomas P. Steindler In Support of Opposition To Plexxikon’s Motion in Limine No. 3 re: Cumulative Expert Testimony	¶¶ 57–59, 77–80	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 287 – DENIED			
Dkt. No. 288-3/ (287-3)	Exhibit B to the Declaration of Thomas P. Steindler In Support Of Novartis’s Opposition to Plexxikon’s Motion in Limine No. 4 re: Excluding Withheld Evidence	Entire document	DENIED (Defendant states, in conclusory fashion, that the document “contain[s] and refer[s] to competitively sensitive documents the public disclosure of which would cause harm to Novartis.” See Dkt. No. 287-1. This generic explanation is insufficient to establish good cause.)
Dkt. No. 288-4/ (287-4)	Exhibit C to the Declaration of Thomas P. Steindler In Support Of Novartis’s Opposition to Plexxikon’s Motion in Limine No. 4 re: Excluding Withheld Evidence	Entire document	DENIED (Defendant states, in conclusory fashion, that the document “contain[s] and refer[s] to competitively sensitive documents the public disclosure of which would cause harm to Novartis.” See Dkt. No. 287-1. This generic explanation is insufficient to establish good cause.)
Dkt. No. 289 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 290/ (289-4)	Opposition To Plexxikon’s Motion in Limine No. 5 re: Excluding Hidden Hearsay Testimony	Page 1:21–23; Page 2:20–25; Page 3:1–8; Page 5:3	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

			No. 301.)
Dkt. No. 290-2/ (289-5)	Exhibit A to the Declaration of Thomas P. Steindler In Support of Opposition To Plexxikon’s Motion in Limine No. 5 re: Excluding Hidden Hearsay Testimony	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 291 – DENIED			
Dkt. No. 292/ (291-3)	Plaintiff’s Opposition to Novartis’s Motion in Limine No. 1 Re: PTAB Proceedings	Page 2:7–10	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 292-6/ (291-5)	Exhibit 5 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 1 Re: PTAB Proceedings	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 292-8/ (291-7)	Exhibit 7 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 1 Re: PTAB Proceedings	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 292-9/ (291-9)	Exhibit 8 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 1 Re: PTAB Proceedings	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 293 – DENIED			
Dkt. No. 294/ (293-3)	Plaintiff’s Opposition to Novartis’s Motion in Limine No. 2 re: Unasserted Patents as Evidence of the Validity of the Asserted Patents	Page 2:3–5, 11–16	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 294-3/ (293-5)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 2 re:	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Unasserted Patents as Evidence of the Validity of the Asserted Patents		
Dkt. No. 294-5/ (293-7)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 2 re: Unasserted Patents as Evidence of the Validity of the Asserted Patents	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 295 – DENIED			
Dkt. No. 296-2/ (295-3)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 3 re: Evidence or Argument Mischaracterizing or Having a Tendency to Mislead as to the Scope of Plexxikon's Patent Rights	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 296-3/ (295-5)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff's Opposition to Novartis's Motion in Limine No. 3 re: Evidence or Argument Mischaracterizing or Having a Tendency to Mislead as to the Scope of Plexxikon's Patent Rights	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 297 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 326/ (297-4)	Plaintiff's Opposition to Novartis's Motion in Limine No. 4 Re: Alleged Copying	Page 1:19–24 Page 2:9, 17–28 Page 3:1–5, 8–20	GRANTED (Contains licensing negotiation, as well as proprietary pharmaceutical research and development information. See Dkt. No. 302.)
Dkt. No. 326-2/ (297-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of	Entire document	GRANTED (Contains proprietary pharmaceutical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Plaintiff’s Opposition to Novartis’s Motion in Limine No. 4 Re: Alleged Copying		research and development information. See Dkt. No. 302.)
Dkt. No. 326-3/ (297-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 4 Re: Alleged Copying	Entire document	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 302.)
Dkt. No. 316/ (297-10)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 4 Re: Alleged Copying	Entire document	GRANTED (Contains licensing negotiation, as well as proprietary pharmaceutical research and development information. See Dkt. No. 302.)
Dkt. No. 298-5/ (297-12)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 4 Re: Alleged Copying	Entire document	GRANTED (Contains licensing negotiation, as well as proprietary pharmaceutical research and development information. See Dkt. No. 302.)
Dkt. No. 298-6/ (297-14)	Exhibit 5 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 4 Re: Alleged Copying	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 298-7/ (297-16)	Exhibit 6 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 4 Re: Alleged Copying	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 298-8/ (297-18)	Exhibit 7 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Limine No. 4 Re: Alleged Copying		
Dkt. No. 299 – DENIED			
Dkt. No. 327-4/ (299-4)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 327-5/ (299-6)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 306 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 307/ (306-4)	Defendant’s Notice of Motion and Motion to Strike Second Supplemental Report of Plaintiff’s Expert Gregory K. Leonard, Ph.D.	Page:2:25–28 Page 6:25–26 Page 8:11 Page 9:10, 17–26 Page 10:1–14, 24–28 Page 11:1–14, 16–18 Page 13:4–10 Page 14:22–23 Page 15:1–9, 17–20 Page 16:4, 7–11, 20–22, 24–27 Page 17:1–8	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 307-2/ (306-5)	Exhibit 1 to the Declaration of Thomas P. Steindler In Support Of Defendant’s Motion To Strike Second Supplemental Report of Plaintiff’s Expert Gregory K. Leonard, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 307-3/ (306-7)	Exhibit 2 to the Declaration of Thomas P.	¶ 59, & n.75 Figure 4	GRANTED (Contains licensing

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Steindler In Support Of Defendant’s Motion To Strike Second Supplemental Report of Plaintiff’s Expert Gregory K. Leonard, Ph.D.	¶¶ 75–77, & n.112, 115, 117 ¶ 79, & n.118 ¶¶ 112–114, & n.194 Exhibit 3 (pages 1 and 2)	negotiation terms. See Dkt. No. 312.)
Dkt. No. 307-4/ (306-8)	Exhibit 3 to the Declaration of Thomas P. Steindler In Support Of Defendant’s Motion To Strike Second Supplemental Report of Plaintiff’s Expert Gregory K. Leonard, Ph.D.	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 314 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 325/ (314-5)	Plaintiff’s Opposition to Defendant’s Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 3:16–22, 23–24, 26	GRANTED (Contains trade secrets and licensing negotiation terms. See Dkt. No. 314.)
Dkt. No. 325/ (314-5)	Plaintiff’s Opposition to Defendant’s Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 1:17–18 Page 2:3–13 Page 4:6–7 Page 5:1	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 325-2/ (314-7)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Defendant’s Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.	Page 29, ¶ 59 Page 40, ¶ 79 Page 41, n.112 Page 42, n.117, 118 Page 44, ¶ 83 Page 45, ¶¶ 83–85 Page 46, ¶¶ 85–86, n.132–134 Page 47, ¶¶ 86–88, n.135 Page 48, ¶¶ 88–89, n.139–140 Page 58, ¶¶ 102, 104 Page 59, ¶ 104 Page 60, ¶¶ 106–107 Page 61, ¶¶ 107–109, n.185 Page 62, ¶¶ 109–110, n.188 Page 65, ¶¶ 113–114, n.194 Page 66, ¶ 114 Page 81, ¶ 144, n.231	GRANTED (Contains trade secrets and licensing negotiation terms. See Dkt. No. 314.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

<p>Dkt. No. 325-2/ (314-7)</p>	<p>Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Defendant’s Motion to Exclude Expert Testimony of Gregory K. Leonard, Ph.D.</p>	<p>Page 28, ¶ 57 Page 29, ¶ 60 Page 30, Figure 4 Page 31, ¶¶ 62–63 Page 32, ¶¶ 63–65 Page 33, ¶¶ 65–66, n.88 Page 34, ¶ 68 Page 35, ¶¶ 68–69, n.93, 95 Page 36, ¶ 70 Page 37, ¶ 72 Page 38, ¶¶ 72–73, n.102, 104 Page 39, ¶¶ 73–74, n.107 Page 40, n.110 Page 44, ¶ 81 Page 68, ¶¶ 117–118 Page 69, ¶¶ 119–120 Page 70, ¶¶ 120–121 Page 71, ¶¶ 122–123 Page 72, ¶¶ 124–125 Page 73, ¶¶ 126–127 Page 74, ¶¶ 127–128, n.219 Page 75, ¶¶ 128–131 Page 76, ¶¶ 131–132, n.222 Page 77, ¶¶ 132–135</p>	<p>GRANTED IN PART (The following contains proprietary pharmaceutical research and development information:</p> <ul style="list-style-type: none"> • Page 44, ¶ 81 • Page 68, ¶¶ 117–118 • Page 69, ¶¶ 119–120 • Page 70, ¶¶ 120–121 • Page 71, ¶¶ 122–123 • Page 72, ¶¶ 124–125 • Page 73, ¶¶ 126–127 • Page 74, ¶¶ 127–128, n.219 • Page 75, ¶¶ 128–131 • Page 76, ¶¶ 131–132, n.222 • Page 77, ¶¶ 132–135 <p>See Dkt. No. 330.)</p>
<p>Dkt. No. 316/ (314-9)</p>	<p>Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 4 Re: Alleged Copying</p>	<p>Page 44, ¶ 83</p>	<p>GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 314.)</p>
<p>Dkt. No. 327-2/ (314-11)</p>	<p>Exhibit 1 to the Declaration of Laura E. Miller in Support of Plexxikon’s Opposition to Novartis’s Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018</p>	<p>Page 2:20–27 Page 3:1–28 Page 4:1–2, 4–27 Page 5:8–9</p>	<p>GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 314.)</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dkt. No. 327-3/ (314-13)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plexxikon’s Opposition to Novartis’s Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Page 14:8–10	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 314.)
Dkt. No. 327-4/ (314-15)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Page 65, ¶ 113 Page 66, ¶ 114	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 314.)
Dkt. No. 327-4/ (314-15)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Page 27, ¶ 56 Page 27–28, ¶ 57	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 327-5/ (314-17)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018	Exhibits 2a, 2b, 3, and 4	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 314.)
Dkt. No. 327-5/ (314-17)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to	Page 1–2, ¶ 4 Exhibits 5a, 5b, 5c, and 6	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Novartis’s Motion in Limine No. 5 Re: Evidence or Argument Suggesting Damages Should be Awarded for Any Period After December 2018		
Dkt. No. 319/ (314-19)	Exhibit 4 to the Declaration of Thomas P. Steindler in Support of Defendant’s Motion to Strike Second Supplemental Report of Plaintiff’s Expert Gregory K. Leonard, Ph.D.	Page 2:20–27 Page 3:1–28 Page 4:1–2, 4–27 Page 5:8–9	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 314.)
Dkt. No. 319/ (314-19)	Exhibit 4 to the Declaration of Thomas P. Steindler in Support of Defendant’s Motion to Strike Second Supplemental Report of Plaintiff’s Expert Gregory K. Leonard, Ph.D.	Page 6:2–3	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 332 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 333/ (332-4)	Plaintiff’s Opposition to Novartis’s Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 6:26–27 Page 16:20–21	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 333-4/ (332-6)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 2:20–27 Pages 3–4 Page 5:8–9	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)
Dkt. No. 333-5/ (332-8)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 14:8–10	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)
Dkt. No. 333-6/ (332-10)	Exhibit 5 to the Declaration of Laura E. Miller in Support of	Pages 23–24, ¶ 51, n.55 Page 25, ¶ 53, n.63–64 Pages 27–28, ¶¶ 56–57,	GRANTED IN PART (The following

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Plaintiff’s Opposition to Novartis’s Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	n.72 Pages 34–36, ¶¶ 68–70, n.93, 95 Pages 37–38, ¶¶ 72–73, n.102, 104	contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page 25, ¶ 53, n.63–64 • Pages 27–28, ¶ 57, n.72 See Dkt. No. 334.)
Dkt. No. 333-6/ (332-10)	Exhibit 5 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Page 41, ¶ 76, n.112 Page 42, n.117–118 Page 58, ¶¶ 102, 104 Page 61–62, ¶¶ 107–110, n.185 Page 65–66, ¶¶ 113–114, n.194 Page 85, ¶ 153 Exhibit 3 (pages 1 and 2)	GRANTED (Contains trade secret and licensing negotiation terms. See Dkt. No. 332.)
Dkt. No. 333-7/ (332-12)	Exhibit 6 to the Declaration of Laura E. Miller in Support of Plaintiff’s Opposition to Novartis’s Motion to Strike the Second Supplemental Report of Dr. Gregory K. Leonard	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 363 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 364/ (363-4)	Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 2	Page 1:14–15, 20–23 Page 8:13–17 Page 9:1–2	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 364-2/ (363-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 2	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 364-3/ (363-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 2	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 364-5/ (363-10)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof	Entire document	GRANTED (Contains proprietary manufacturing information. See Dkt.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Re: Novartis’s Motion in Limine No. 2		No. 370.)
Dkt. No. 364-7/ (363-12)	Exhibit 6 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 2	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 364-10/ (363-14)	Exhibit 9 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 2	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 366 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 367/ (366-5)	Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 3	Page 16:10	GRANTED (Contains confidential sales information. See Dkt. No. 366.)
Dkt. No. 367/ (366-5)	Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 3	Page 6:3–11 Page 11:7–28 Page 12:1–18 Page 13:1–14 Page 14:6–18 Page 16:3, 21–22 Page 19:18–19, 27 Page 21:13–20	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page 11:7–28 • Page 12:1–18 • Page 13:1–14 See Dkt. No. 371.)
Dkt. No. 367-2/ (366-7)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 3	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 367-3/ (366-9)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 3	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 367-4/ (366-11)	Exhibit 3 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Re: Novartis’s Motion in Limine No. 3		
Dkt. No. 367-5/ (366-13)	Exhibit 4 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 3	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 368 – GRANTED IN PART and DENIED IN PART			
Dkt. No. 369/ (368-4)	Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 4	Page 1:9–10 Page 2:6–9 Page 3:16–20, 22–25 Page 4:2–7, 11–12, 27–28 Page 5:1, 7–9, 12–16, 17–27 Page 6:3–6, 12–14, 16–28 Page 7:1, 4–24, 26–28 Page 8:1–5, 13–16 Page 9:4, 11–16, 18–28 Page 10:1, 9–13 Page 11:1–4, 6–16 Page 12:15–24 Page 13:1, 4–6, 8–14, 17–20, 23–24, 28 Page 14:1–5	GRANTED IN PART (The following contains proprietary pharmaceutical research and development information: <ul style="list-style-type: none"> • Page 1:9–10 • Page 2:6–9 • Page 3:16–20, 22–25 • Page 4:2–7, 11–12, 27–28 • Page 5:1, 7–9, 12–27 • Page 6:4–7, 13–15, 17–28 • Page 7:1–2, 5–25, 27–28 • Page 8:1–6, 15–17; • Page 9:20–25, 27–28 • Page 10:1–10, 18–22 • Page 12:26–28 • Page 13:1–8, 11–13 • Page 14:2–3, 11–15 • Page 15:6, 14, 19 See Dkt. No. 372.)
Dkt. No. 369-2/ (368-6)	Exhibit 1 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


	Re: Novartis’s Motion in Limine No. 4		
Dkt. No. 369-3/ (368-8)	Exhibit 2 to the Declaration of Laura E. Miller in Support of Plaintiff’s Offer of Proof Re: Novartis’s Motion in Limine No. 4	Entire document	DENIED (No supporting declaration filed. See Civ. L.R. 79-5(e)(1).)
Dkt. No. 374 – GRANTED			
Dkt. No. 375/ (374-4)	Offer of Proof Relating to Plaintiff’s Motion in Limine No. 1	Page 10:3–27 Page 11:1–21 Page 12:19–21 Page 13:3–18, 21–27 Page 14:1–6, 8–9, 11–20, 22–27 Page 15:1, 3–4, 6–8 Page 21:22–23 Page 22:1–12, 14–26 Page 23:3–4, 7, 9, 21–22, 24–26 Page 24:3, 5, 10, 19–22, 24–26 Page 25:1, 15–25 Page 26:2–6, 8–25 Page 27:1–4, 6–22, 26–28 Page 35:11–27 Page 36:1–26 Page 37:1–13 Page 50:23 Page 51:1–6, 18–20	GRANTED (Contains proprietary pharmaceutical research and development information. See Dkt. No. 377.)

III. CONCLUSION

The Court **GRANTS IN PART** and **DENIES IN PART** the parties’ administrative motions to file under seal. Pursuant to Civil Local Rule 79-5(f)(1), documents filed under seal as to which the administrative motions are granted will remain under seal. The Court **DIRECTS** the parties to file public versions of all documents for which the proposed sealing has been denied, as indicated in the chart above, within seven days from the date of this order.

IT IS SO ORDERED.

Dated: 3/13/2020


 HAYWOOD S. GILLIAM, JR.
 United States District Judge